Literature DB >> 8434610

Gaucher disease: gene frequencies in the Ashkenazi Jewish population.

E Beutler1, N J Nguyen, M W Henneberger, J M Smolec, R A McPherson, C West, T Gelbart.   

Abstract

DNA from over 2,000 Ashkenazi Jewish subjects has been examined for the four most common Jewish Gaucher disease mutations, which collectively account for about 96% of the disease-producing alleles in Jewish patients. This population survey has made possible the estimation of gene frequencies for these alleles. Eighty-seven of 1,528 individuals were heterozygous for the 1226G (N370S) mutation, and four presumably well persons were homozygous for this mutation. The gene frequency for the 1226G allele was calculated to be .0311, and when these data were pooled with those obtained previously from another 593 Jewish subjects, a gene frequency of .032 with a standard error of .004 was found. Among 2,305 normal subjects, 10 were found to be heterozygous for the 84GG allele, giving a gene frequency of .00217 with a standard error of .00096. No examples of the IVS2(+1) mutation were found among 1,256 samples screened, and no 1448C (L444P) mutations were found among 1,528 samples examined. Examination of the distribution of Gaucher disease gene frequencies in the general population shows that the ratio of 1226G mutations to 84GG mutations is higher than that in the patient population. This is presumed to be due to the fact that homozygotes for the 1226G mutation often have late-onset disease or no significant clinical manifestations at all. To bring the gene frequency in the patient population into conformity with the gene frequency in the general population, nearly two-thirds of persons with a Gaucher disease genotype would be missing from the patient population, presumably because their clinical manifestations were very mild.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8434610      PMCID: PMC1682129     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  4 in total

Review 1.  Gaucher's disease.

Authors:  E Beutler
Journal:  N Engl J Med       Date:  1991-11-07       Impact factor: 91.245

2.  High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews.

Authors:  A Zimran; T Gelbart; B Westwood; G A Grabowski; E Beutler
Journal:  Am J Hum Genet       Date:  1991-10       Impact factor: 11.025

3.  Frequency of carriers of chronic (type I) Gaucher disease in Ashkenazi Jews.

Authors:  Y Matoth; S Chazan; A Cnaan; I Gelernter; C Klibansky
Journal:  Am J Med Genet       Date:  1987-07

4.  Mutations in Jewish patients with Gaucher disease.

Authors:  E Beutler; T Gelbart; W Kuhl; A Zimran; C West
Journal:  Blood       Date:  1992-04-01       Impact factor: 22.113

  4 in total
  50 in total

1.  Geographic distribution of disease mutations in the Ashkenazi Jewish population supports genetic drift over selection.

Authors:  Neil Risch; Hua Tang; Howard Katzenstein; Josef Ekstein
Journal:  Am J Hum Genet       Date:  2003-02-24       Impact factor: 11.025

2.  A population-genetic test of founder effects and implications for Ashkenazi Jewish diseases.

Authors:  Montgomery Slatkin
Journal:  Am J Hum Genet       Date:  2004-06-18       Impact factor: 11.025

3.  Alglucerase for Gaucher's disease: dose, costs and benefits.

Authors:  E Beutler; A M Garber
Journal:  Pharmacoeconomics       Date:  1994-06       Impact factor: 4.981

4.  Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase.

Authors:  Samarjit Patnaik; Wei Zheng; Jae H Choi; Omid Motabar; Noel Southall; Wendy Westbroek; Wendy A Lea; Arash Velayati; Ehud Goldin; Ellen Sidransky; William Leister; Juan J Marugan
Journal:  J Med Chem       Date:  2012-06-08       Impact factor: 7.446

5.  Bone marrow involvement in Gaucher disease at MRI : what long-term evolution can we expect under enzyme replacement therapy?

Authors:  Benjamin Fedida; Sébastien Touraine; Jerôme Stirnemann; Nadia Belmatoug; Jean-Denis Laredo; David Petrover
Journal:  Eur Radiol       Date:  2015-04-16       Impact factor: 5.315

6.  Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention.

Authors:  Zhanqian Yu; Anu R Sawkar; Lisa J Whalen; Chi-Huey Wong; Jeffery W Kelly
Journal:  J Med Chem       Date:  2007-01-11       Impact factor: 7.446

7.  The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients.

Authors:  Tamar H Taddei; Katherine A Kacena; Mei Yang; Ruhua Yang; Advitya Malhotra; Michael Boxer; Kirk A Aleck; Gadi Rennert; Gregory M Pastores; Pramod K Mistry
Journal:  Am J Hematol       Date:  2009-04       Impact factor: 10.047

8.  A microfluidic device with fluorimetric detection for intracellular components analysis.

Authors:  Radosław Kwapiszewski; Maciej Skolimowski; Karina Ziółkowska; Elżbieta Jędrych; Michał Chudy; Artur Dybko; Zbigniew Brzózka
Journal:  Biomed Microdevices       Date:  2011-06       Impact factor: 2.838

9.  Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease.

Authors:  L N Clark; B M Ross; Y Wang; H Mejia-Santana; J Harris; E D Louis; L J Cote; H Andrews; S Fahn; C Waters; B Ford; S Frucht; R Ottman; K Marder
Journal:  Neurology       Date:  2007-09-18       Impact factor: 9.910

10.  The frequency of the C854 mutation in the aspartoacylase gene in Ashkenazi Jews in Israel.

Authors:  O N Elpeleg; Y Anikster; V Barash; D Branski; A Shaag
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.